Trials / No Longer Available
No Longer AvailableNCT03317366
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- —
Summary
ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent access to ARQ 092 through an existing clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 092 | Open-label expanded access for ARQ 092 capsules |
Timeline
- First posted
- 2017-10-23
- Last updated
- 2021-08-06
Source: ClinicalTrials.gov record NCT03317366. Inclusion in this directory is not an endorsement.